Speakers Include Biologics Drug Discovery Biologics Research Technology Innovation

Transcription

1 Day 1 Stream 1 - Peptide Discovery and Synthesis Peptide Library, Display and Array Technologies Peptide Synthesis; Biosynthesis and Modified Peptides Rational and Structure-Based Design of Novel Peptides Peptide Self-Assembly; Producing Molecular Building Blocks Discovering and Producing Bioactive Peptides Small Molecules to Inhibit Protein-Protein Interactions Day 2 Stream 1 - Peptide Development and Optimisation Designing Optimal Peptides; Peptidomimetics Peptide Conjugation Techniques Cell Penetrating Peptides in Drug Delivery Peptide Delivery Systems Antimicrobial Peptides in Immunotherapy Discovery and Development of Protease Inhibitors Peptide-Based Drug Discovery Peptide Aggregation Tools Oxford Global Conferences Are Proud To Present The Oxford Global Peptides Congress will be held on the 3 rd & 4 th April, 2014 at the Novotel London West, UK. Our esteemed experts will explore recent developments in peptide research from discovery and synthesis through to optimal engineering techniques and therapeutic applications. The popularity of peptide therapeutics has increased significantly in recent years; the number of new peptides entering the clinic has doubled, and peptide therapies in the US have achieved sales over $1 billion. The Peptides Congress will bring together key decision makers and researchers in this revitalised field. On Day One, the Congress will examine various peptide discovery and synthesis techniques, whilst looking in detail at the design and production of peptide libraries and arrays, as well as synthesised and modified peptides. Our internationally renowned speakers will also give a detailed insight into protein-protein interactions and the production of bioactive peptides. Due to their compelling potential, many major pharmaceuticals are seeing a resurgence of peptide use in their pipelines. The therapeutic potential of peptides is being embraced by the industry, and offers many novel opportunities for drug discovery. Day Two of the Congress will see discussions focus on peptide engineering, including peptidomimetics and peptide conjugation, as well as cell-penetrating peptides. Additionally, our experts will discuss the potential of antimicrobial peptides in immunotherapy and as protease inhibitors in drug discovery. The Peptides Congress will be co-located with our 7 th Annual Proteins Congress Speakers Include Who You Will Meet Thomas Vorherr Graham Simpson Joël Richard Novartis GSK Ipsen 220 senior attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, academics, CRO and solution provider companies will be attending. Meet Senior VPs, Directors, & Managers with the following job titles: Protein and Peptide Chemistry Therapeutic Peptide Chemistry Discovery Technologies Biologics Drug Discovery Biologics Research Technology Innovation Molecular Biology Peptide Development Peptide Optimisation Networking And Business Meeting Opportunities Meet face-to-face with leading solution providers and senior-level industry peers through a series of formal and informal networking opportunities. Categories of solution provider include: Peptide Chemistry Peptide Synthesis Peptide Coupling Bioproduction Amino Acid Synthesis Peptide Libraries Peptide Arrays Peptide Immunisation Peptide Conjugation

2 Confirmed Speakers: Andrew A Young, VP and Head, Enteroendocrine Biology, GlaxoSmithKline Graham Simpson, Head, Therapeutic Peptide CPU, GlaxoSmithKline Volker Schellenberger, President, Amunix Operating Inc Janos T. Kodra, Principal Scientist, Protein & Peptide Chemistry 3, Novo Nordisk Les Miranda, Director, Peptide Research & Discovery, Therapeutic Discovery, Amgen Thomas Vorherr, Director Peptide Discovery, Novartis Institutes for BioMedical Research Joël Richard, Vice President Peptides, CMC & Engineering, Ipsen Jesper Lau, Vice President, Diabetes Protein & Peptide Chemistry, Novo Nordisk Fernando Albericio, General Director, Barcelona Science Park, Professor, University of Barcelona, Group Leader, Barcelona Biomedical Research Institute Ronald Swanson, Sr. Director of Lead Discovery and Optimization for Biologics Research, Janssen Pharmaceuticals Biotechnology Center of Excellence Adrian Podmore, Formulation Scientist, MedImmune Maria A Bednarek, Principal Scientist and Head of Peptide Chemistry, MedImmune Anna Collen, Director Reagent and Assay Development, AstraZeneca Spiros Liras, VP, CVMED Medicinal Chemistry, Pfizer Darryl Davis, Principal Research Scientist, Janssen Pharmaceutical R&D Stefan Geschwindner, Principal Scientist Biophysics & icoach, AstraZeneca R&D William J. Lambert, Fellow, Drug Delivery and Device Development, MedImmune Christophe Bonny, CSO, Bicycle Therapeutics Tom Loughman, Ph.D., Director of API Development, Ipsen, Ireland Filip Cuyckens, Principal Scientist and Head of Analytical Sciences, Janssen Research and Development Chantal Alcouffe, Medicinal Chemist Group Leader, Sanofi Eike Hoffmann, Senior Scientist and Group Leader, Roche Fabrizio Giordanetto, Project Leader and Principal Scientist, AstraZeneca Michael Shapiro, Director of Analytical Chemistry, Pfizer Chris Herring, Manager, Head of Protein Sciences, GlaxoSmithKline Brian Austin, Professor of Protein Science, St George s University of London

3 Day One 3 rd April Registration Oxford Global s Welcome Address Chairperson s Opening Address Keynote Address: Keynote Address is colocated. This will take place in Proteins Room 1 Peptide Discovery and Synthesis Stream Keynote Address: Peptide Hormone Drug Candidates Andrew A Young, VP and Head, Enteroendocrine Biology, GlaxoSmithKline Solution Provider Presentation Coffee & Refreshments One to One Meetings x3 Poster Presentation Sessions Stabilised Peptides for Intracellular Protein-Protein Interactions Building an understanding of druggable chemical space to identify overlap of cellularly permeable PPI inhibitors Strategies to improve and impart cellular permeability Graham Simpson, Head, Therapeutic Peptide CPU, GlaxoSmithKline Peptide Reagents and Assays; Challenges and Solutions: To be confirmed Anna Collen, Director Reagent and Assay Development, AstraZeneca Solution Provider Presentation Lunch Pharmaceutical Engineering of Proteins and Peptides Jesper Lau, Vice President, Diabetes Protein & Peptide Chemistry, Novo Nordisk Challenges for the Discovery of Permeable Therapeutic Peptides Methods suitable for peptidic hit identification Status-quo for intracellular transport of peptides Understanding scope & limitations for oral bioavailability for peptides Thomas Vorherr, Director Peptide Discovery, Novartis Institutes for BioMedical Research Solution Provider Presentation Afternoon Refreshments One to One Meetings x 2 Poster Presentation Sessions Bicycles: High Affinity Bi-Cyclic Peptides from Phage Display Libraries Christophe Bonny, CSO, Bicycle Therapeutics Stapled Vasoactive Intestinal Peptide (VIP) Derivatives Improve VPAC2 Agonism and Glucose- Dependent Insulin Secretion but Not Protease Stability and Cell Permeability Fabrizio Giordanetto, Project Leader and Principal Scientist, AstraZeneca Peptide Structure Determination Using NMR: To be confirmed Michael Shapiro, Director of Analytical Chemistry, Pfizer

4 Day One 3 rd April The Protein-Protein Interaction Challenge: Experience and Strategies for High Value Intractables Success in finding small-molecule modulators of PPIs is intimately linked with the ligandability of the respective target as well as the applied strategy for the identification of leads Given the multitude of approaches that show promising results in identifying PPI modulators, targets will require tailored strategies to effectively deliver a range of starting points worth considering for lead generation Examples will be shown for assessing target ligandability as well as employing a range of approaches including fragment-based screening and encoded library technologies for delivering promising starting points, and the pros and cons of those approaches will be discussed in detail Stefan Geschwindner, Principal Scientist Biophysics & icoach, AstraZeneca R&D Synthesis of Marine Cyclodepsipeptides with Cytotoxic Activity Fernando Albericio, General Director, Barcelona Science Park, Professor, University of Barcelona, Group Leader, Barcelona Biomedical Research Institute Molecular Mechanism of SSR128129E, an Extracellularly Acting Small Molecule Allosteric Inhibitor of FGF Receptor Signalling Chantal Alcouffe, Medicinal Chemist Group Leader, Sanofi Networking Drinks End of Day One

5 Day Two 4 th April Conference Room: Stream Chair: Keynote Address: Peptide-Based Drugs; Oral Delivery Through Passive Permeability: To be confirmed Spiros Liras, VP, CVMED Medicinal Chemistry, Pfizer Peptide Development and Optimisation Stream Keynote Address: Pharmaceutical Optimization of Toxin Peptides The identification of large or small molecules which potently, effectively, and safely modulate ion channels, attractive therapeutic targets for the treatment of human diseases, remains particularly difficult in contemporary drug discovery Although toxin peptides are novel therapeutic candidates for a range of medical indications through ion channel targeting, their clinical application have so far been primarily limited to cases where localized administration has been suitable. One of the obstacles to the increased clinical development of toxin peptides has been availability of effective methods for engineering desirable pharmaceutical properties from novel toxin peptide leads To better realize the therapeutic potential of toxin peptides more useful and efficient pharmaceutical optimization technologies must be developed, and in turn, applied Here we discuss approaches for the improvement of the pharmaceutical properties of an ion channel targeting toxin peptide Les Miranda, Director, Peptide Research & Discovery, Therapeutic Discovery, Amgen Solution Provider Presentation Morning Coffee & Poster Presentations One to One Meetings x2 Poster Presentation Sessions Peptide Delivery: What is the Present Status and What is Coming in the Future? Challenges and Drivers for Innovative Peptide Delivery Systems Solid Depot Peptide Delivery Systems Soft Depot Peptide Delivery Systems Water-Based Self-Assembling Systems and Gels Alternative Routes of Administration Joël Richard, VP Peptides, Ipsen Solution Provider Presentation Wearable Bolus Injectors (Patch Pumps) for Subcutaneous Delivery This presentation will Discuss challenges to delivering large volumes subcutaneously Review patch pump technologies in development William J. Lambert, Fellow, Drug Delivery and Device Development, MedImmune Lunch Engineering Novel Therapeutics Targeting the Kv1.3 Ion Channel Kv1.3 as a target Venom peptides as therapeutics Engineering venom peptides for potency and specificity Use of mammalian expression libraries for peptide engineering Fusion partner and linker optimization Ronald Swanson, Sr. Director of Lead Discovery and Optimization for Biologics Research, Janssen Pharmaceuticals Biotechnology Center of Excellence Strategies and Tools for Studying the Metabolism of Peptide Drug Candidates Why do we want to study the metabolism of peptide drugs? Metabolism studies for peptides with a natural amino acid sequence versus those containing unnatural amino acids Novel techniques and methodologies; which tools are best suited for the job? Illustrations with case examples Filip Cuyckens, Principal Scientist and Head of Analytical Sciences, Janssen Research and Development

6 Day Two 4 th April Application of High Resolution MS for the Analysis and Characterisation of Peptide APIs Use of high resolution MS for the characterisation of peptide therapeutics during peptide synthesis and manufacturing Quantifying, quality control, and identifying impurities Tom Loughman, Ph.D., Director of API Development, Ipsen, Ireland Afternoon Refreshments Design of Glucagon-Like Peptide-1 Agonists Glucagon-like peptide-1 (GLP-1) is a 30 amino acid peptide hormone secreted from the L-cells of the small intestine in response to nutrient intake. The biological actions of GLP-1 include glucose-dependent insulin secretion, insulin biosynthesis, inhibition of Glucagon secretion, gastric emptying, inhibition of appetite and lowering of food intake. These features have made GLP-1 based therapy an attractive target for the treatment of diabetes. We have used a combination of an evolutionary approach and traditional medicinal chemistry to understand structure activity relationship of the GLP-1 hormone. The talk will focus on our findings on that journey Janos T. Kodra, Principal Scientist, Protein & Peptide Chemistry 3, Novo Nordisk Protein-Peptide Ligation; Coupling Peptides to Antibodies: To be confirmed Eike Hoffmann, Senior Scientist and Group Leader, Roche Tools for Analysis of Peptide Aggregation Pathways During Formulation Mechanisms of protein peptides aggregation Methods & principles Strategies to understand aggregation pathways Case study Adrian Podmore, Formulation Scientist, MedImmune XTEN A Biodegradable and Monodisperse PEG Alternative for Peptide Conjugation Amunix has developed XTEN, a protein-based polymer that mimics the biophysical properties of PEG but without its limitations. XTEN can be produce in high-titer microbial fermentation yielding a polymer that with chemically defined structure and a precisely defined number and location of conjugation sites. Peptides and other moieties can be efficiently conjugated to XTEN yielding products with long in vivo half-life. Conjugation reactions and product stability can be easily monitored by mass spectrometry. Unlike PEG, XTEN is easily metabolized, thereby eliminating the risk of kidney epithelial vacuolation. Single or multiple payloads can be conjugated to XTEN which allows the generation of monospecific, bispecific as well as multivalent pharmaceutical formats. Multiple examples of XTENylated biologics, including two clinical programs, will be discussed. Volker Schellenberger, President, Amunix Operating Inc High Affinity Peptide Antagonists: To be confirmed Maria A Bednarek, Principal Scientist and Head of Peptide Chemistry, MedImmune Development of Platform Analytics to Support the Lifecycle of Peptide Therapeutics Darryl Davis, Principal Research Scientist, Janssen Pharmaceutical R&D Peptide-Based Drug Discovery: To be confirmed Chris Herring, Manager, Head of Protein Sciences, GlaxoSmithKline Brain Penetration of Peptide Contrast Agents for MRI Diagnosis of Alzheimer's Disease Brian Austin, Professor of Protein Science, St George s University of London End of Conference

7 PEPTIDES CONGRESS 3rd & 4th April 2014, Novotel London West Hotel London, UK HOW TO REGISTER Please complete your personal and payment details in the space provided below and return the form via fax on :- +44 (0) Delegate Details Registration Fees Please complete fully and clearly. Please photocopy for additional delegates Standard Price (VAT is charged at 20%) Title: Forename: Surname: Job Title: Company/Organisation: Address: Industry delegates (Biopharma, Pharma or Biotech Companies) Academic delegates Vendor delegates (CRO s, Consultants, Technology and Service Providers) VAT VAT VAT Postcode: Country: Direct Telephone Direct Fax: Mobile: Switchboard: Signature: Date: How to Pay (choose one of the following payment options) Number of delegates: Industry del(s) Academic dels(s) Vendor dels(s) CREDIT CARD: Visa MasterCard Maestro Amex Credit Card Number: Valid from: / Expiry Date: / Security code: Cardholders name: Signature: Date: PLEASE INVOICE ME: Invoice ADDRESS (if different from above *Please note there is a 50 handling charge for payment via invoice. *Payment by credit card is subject to 3% bank charge or 4% AMEX. Special Offer 3 for 2 Offer* *Offer only valid for industry delegates only. Please contact us for further details on the address below. Terms & Conditions Agreed Terms between the Organiser (Oxford Global) and the Delegate: Delegate Booking Fee The Delegate Booking Fee includes: all meals throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of 50 will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online. Meeting Choices Industry Delegates eligible to participate in the organised meetings must complete the online Meeting Wish List issued by the Organiser at least 15 working days before the Event or the Organiser will select the most appropriate Solution Providers on behalf of the Delegate. The Organiser will prepare a schedule of twenty-minute meetings and Delegates will attend the meetings as detailed on the final itinerary sent out at least one week prior to the event. Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global and not via the online booking facility. Poster Presentations Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, , telephone, fax and additional authors, within a month of registration. All poster spaces will be for A1 portrait size. Cancellation and Curtailment Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation. More than 6 months prior 35% cancellation fee / 65% refund Between 6 and 3 months prior 75% cancellation fee/ 25% refund Less than 3 months prior to the event Full cancellation fee / No refund Data Protection The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/ her personal and company information on the terms set out herein. Miscellaneous This Agreement may not be transferred or assigned by either the Delegate or the Delegate s Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded. I agree to the above Terms and Conditions REGISTER ONLINE at or contact marketing@oxfordglobal.co.uk or call +44 (0)